USP - Universidade de São Paulo
Universidade de São Paulo

Palestra – Dr. Frederic Zecri

 

Título:From Ancient Medicine to the First Oral Treatment of Multiple Sclerosis: The Discovery of FTY720 (Gilenya™).”

.

Dr. Frederic Zecri

Group leader at Novartis Institutes for BioMedical Research, Inc.

Data: 26 de outubro. 17 h.

.

Currículo resumido:.Group LeaderNovartis June 2011 – Present (1 year 5 months) Cambridge, MA, USA

Senior Research Investigator  – Novartis November 2009 – June 2011 (1 year 8 months)

Research InvestigatorNovartis April 2002 – November 2009 (7 years 8 months)

Postdoctoral FellowThe Sripps Research Institut

September 2000 – March 2002 (1 year 7 months)

First total synthesis and biological evaluation of an antibiotic – Thiostrepton – and its analogs. The structure of Thiostrepton is characterized by an assembly of numerous non naturel amino acids, including dehydro-aminoacids, thiazoles, thiazoline, dehydro-piperidine and quinoline moiety.

Pre-PhD internRhone-Poulenc Rorer

August 1998 – January 1999 (6 months)

I worked on developing methodologies (scavengers, parallel purification …) for the solution phase synthesis of libraries of compounds towards potential herbicide application.

Education: Imperial College London – PhD, Organic Synthesis – 1998-2000

Frederic Zecri

Divulgação